Lotte Bjerre Knudsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Recognitions
Lotte Bjerre Knudsen has a total of 520 co-authors. Here are the top co-authors by number of shared publications:
Charles Pyke
Research and Development, Novo Nordisk A/S, Måløv, Denmark
21 shared publicationsJesper Lau
Global Research Technology, Novo Nordisk A/S, Måløv, Denmark
9 shared publications- Peter Madsen
Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark
8 shared publications Jacob Jelsing
Gubra, Hørsholm Kongevej 11B, 2970 Hørholm, Denmark
7 shared publicationsNiels Vrang
Gubra, Hørsholm Kongevej 11B, 2970 Hørholm, Denmark
7 shared publicationsAnna Secher
Global Drug Discovery and
6 shared publications
Latest Publications
- Open Access
Glucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetes
Introduction: Lipids are considered both drivers and biomarkers of cardiometabolic diseases. As glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for diabetes and obesity management, it is crucial to understand how they affect the related comorbidities through the circulating lipidome. This study investigated the lipidomic changes induced by liraglutide treatment when compared to placebo in people with type 2 diabetes (T2D) to characterise lipid remodelling and its association with clinical outcomes. Research design and methods: This post-hoc study analysed plasma samples using liquid chromatography-mass spectrometry (LC-MS/MS) from LIRAFLAME, a randomised, double-blind, placebo-controlled, parallel-group trial. A hundred people with T2D received up to 1.8 mg of liraglutide or placebo once daily for 26 weeks. Plasma samples were collected at baseline, week 13 and week 26. Results: Liraglutide treatment resulted in a statistically significant increase in multiple lysophospholipid subclasses, including LPCs, LPC(O)s, LPC(P)s, LPEs, and LPE(P)s, observed at 13 weeks and sustained at 26 weeks compared to placebo. These increases were not mediated by the change in BMI. Triglyceride concentrations decreased at 13 weeks, while fatty acid levels declined at 26 weeks, consistent with enhanced lipid remodelling. The increase in LPC(O)s was associated with favourable decreases in ALAT, MCP-1, and UACR, suggesting anti-inflammatory effects with hepatic, renal, and cardiovascular benefits. Conclusions: Compared to placebo, 26 weeks of liraglutide treatment resulted in a favourable lipidomic shift from a triglyceride-rich profile towards one enriched in lysophospholipids. This lipid remodelling was associated with improvements in hepatic, renal, and inflammatory markers. Graphical Highlights: Liraglutide upregulates lysophospholipids and lowers triglycerides and fatty acids. The strongest increase was in lysoalkylphosphatidylcholines (LPC(O)s). Lysophosphatidylcholines (LPCs) increased independently of weight loss. LPC(O/P)s associated with improvements in liver, kidney, and inflammation markers.
Open AccessGlucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetes
Introduction: Lipids are considered both drivers and biomarkers of cardiometabolic diseases. As glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for diabetes and obesity management, it is crucial to understand how they affect the related comorbidities through the circulating lipidome. This study investigated the lipidomic changes induced by liraglutide treatment when compared to placebo in people with type 2 diabetes (T2D) to characterise lipid remodelling and its association with clinical outcomes. Research design and methods: This post-hoc study analysed plasma samples using liquid chromatography-mass spectrometry (LC-MS/MS) from LIRAFLAME, a randomised, double-blind, placebo-controlled, parallel-group trial. A hundred people with T2D received up to 1.8 mg of liraglutide or placebo once daily for 26 weeks. Plasma samples were collected at baseline, week 13 and week 26. Results: Liraglutide treatment resulted in a statistically significant increase in multiple lysophospholipid subclasses, including LPCs, LPC(O)s, LPC(P)s, LPEs, and LPE(P)s, observed at 13 weeks and sustained at 26 weeks compared to placebo. These increases were not mediated by the change in BMI. Triglyceride concentrations decreased at 13 weeks, while fatty acid levels declined at 26 weeks, consistent with enhanced lipid remodelling. The increase in LPC(O)s was associated with favourable decreases in ALAT, MCP-1, and UACR, suggesting anti-inflammatory effects with hepatic, renal, and cardiovascular benefits. Conclusions: Compared to placebo, 26 weeks of liraglutide treatment resulted in a favourable lipidomic shift from a triglyceride-rich profile towards one enriched in lysophospholipids. This lipid remodelling was associated with improvements in hepatic, renal, and inflammatory markers. Graphical Highlights: Liraglutide upregulates lysophospholipids and lowers triglycerides and fatty acids. The strongest increase was in lysoalkylphosphatidylcholines (LPC(O)s). Lysophosphatidylcholines (LPCs) increased independently of weight loss. LPC(O/P)s associated with improvements in liver, kidney, and inflammation markers.
- Open Access
- 9 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Semaglutide attenuates neuroinflammation in male mice
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1RA effects on neuroinflammation remain poorly understood. Here we show, using a mouse model of lipopolysaccharide-induced neuroinflammation, how semaglutide coordinates cellular responses to resolve neuroinflammation. We find that semaglutide in male mice prevents brain infiltration of neutrophils, excessive cytokine release, and suppresses neuroinflammation-associated transcriptional signatures specifically in microglia, endothelial cells, and a subset of pericytes. Mechanistically, we identify a subset of Glp1r-expressing neurons in the dorsal vagal complex that, upon semaglutide treatment, regulate genes involved in anti-inflammatory signaling. Semaglutide-modulated pathways overlap with inflammatory signatures found in human neurodegenerative diseases, including Alzheimer's disease, suggesting broad relevance for conditions involving neuroinflammation. Together, these findings reveal how GLP-1R signaling in male mice orchestrates resolution of neuroinflammation through coordinated multi-cellular programs.
- 9 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSemaglutide attenuates neuroinflammation in male mice
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1RA effects on neuroinflammation remain poorly understood. Here we show, using a mouse model of lipopolysaccharide-induced neuroinflammation, how semaglutide coordinates cellular responses to resolve neuroinflammation. We find that semaglutide in male mice prevents brain infiltration of neutrophils, excessive cytokine release, and suppresses neuroinflammation-associated transcriptional signatures specifically in microglia, endothelial cells, and a subset of pericytes. Mechanistically, we identify a subset of Glp1r-expressing neurons in the dorsal vagal complex that, upon semaglutide treatment, regulate genes involved in anti-inflammatory signaling. Semaglutide-modulated pathways overlap with inflammatory signatures found in human neurodegenerative diseases, including Alzheimer's disease, suggesting broad relevance for conditions involving neuroinflammation. Together, these findings reveal how GLP-1R signaling in male mice orchestrates resolution of neuroinflammation through coordinated multi-cellular programs.
- Open Access
- 3 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (4) , 728-740
Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model
Background: CKD is a significant public health issue, affecting approximately half a billion people globally. Key risk factors for CKD include obesity, hypertension, cardiovascular diseases and diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are effective treatments for obesity and diabetes. The FLOW trial recently showed that treatment with the GLP-1RA semaglutide significantly reduced the incidence of clinically important kidney outcomes in patients with type 2 diabetes and CKD, likely via beneficial effects on kidney blood flow, inflammation and fibrosis as well as effects mediated by improvement of glycemic control. This study aimed to characterize the effects of semaglutide in the mouse nephrotoxic serum nephritis model, a non-obese and non-diabetic mouse model of CKD. Methods: Mice were treated with semaglutide or the angiotensin-converting enzyme inhibitor enalapril for 14 days. Various kidney function parameters were measured, and gene expression in key kidney compartments was explored using spatial transcriptomics and single-nucleus RNA sequencing in kidney samples collected at the end of the study. Results: Semaglutide treatment significantly improved kidney function parameters and changed the expression of multiple genes involved in inflammatory processes and fibrosis, such as Spp1, and also affected gene-expression in the renin-angiotensin-aldosterone system. These findings from spatial transcriptomics were validated by histology, which also revealed semaglutide decreased mesangial expansion and had a beneficial effect on filtration slit density in the glomeruli. Conclusions: These findings demonstrate that the beneficial effects of semaglutide treatment in this rodent model of CKD can occur separately from its anti-obesity and anti-diabetes effects.
- 3 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (4) , 728-740
Open AccessMolecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model
Background: CKD is a significant public health issue, affecting approximately half a billion people globally. Key risk factors for CKD include obesity, hypertension, cardiovascular diseases and diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are effective treatments for obesity and diabetes. The FLOW trial recently showed that treatment with the GLP-1RA semaglutide significantly reduced the incidence of clinically important kidney outcomes in patients with type 2 diabetes and CKD, likely via beneficial effects on kidney blood flow, inflammation and fibrosis as well as effects mediated by improvement of glycemic control. This study aimed to characterize the effects of semaglutide in the mouse nephrotoxic serum nephritis model, a non-obese and non-diabetic mouse model of CKD. Methods: Mice were treated with semaglutide or the angiotensin-converting enzyme inhibitor enalapril for 14 days. Various kidney function parameters were measured, and gene expression in key kidney compartments was explored using spatial transcriptomics and single-nucleus RNA sequencing in kidney samples collected at the end of the study. Results: Semaglutide treatment significantly improved kidney function parameters and changed the expression of multiple genes involved in inflammatory processes and fibrosis, such as Spp1, and also affected gene-expression in the renin-angiotensin-aldosterone system. These findings from spatial transcriptomics were validated by histology, which also revealed semaglutide decreased mesangial expansion and had a beneficial effect on filtration slit density in the glomeruli. Conclusions: These findings demonstrate that the beneficial effects of semaglutide treatment in this rodent model of CKD can occur separately from its anti-obesity and anti-diabetes effects.
- Top Cited PapersOpen Access
- 21 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (9) , 3128-3140
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. Here we show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation and reduced hepatic expression of fibrosis-related and inflammation-related gene pathways. Aptamer-based proteomic analyses of serum samples from patients with MASH in a clinical trial identified 72 proteins significantly associated with MASH resolution and semaglutide treatment, with most related to metabolism and several implicated in fibrosis and inflammation. An independent real-world cohort verified the pathophysiological relevance of this signature, showing that the same 72 proteins are differentially expressed in patients with MASH relative to healthy individuals. Taken together, these data suggest that semaglutide may revert the circulating proteome associated with MASH to the proteomic pattern observed in healthy individuals.
- 21 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (9) , 3128-3140
Top Cited PapersOpen AccessModulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. Here we show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation and reduced hepatic expression of fibrosis-related and inflammation-related gene pathways. Aptamer-based proteomic analyses of serum samples from patients with MASH in a clinical trial identified 72 proteins significantly associated with MASH resolution and semaglutide treatment, with most related to metabolism and several implicated in fibrosis and inflammation. An independent real-world cohort verified the pathophysiological relevance of this signature, showing that the same 72 proteins are differentially expressed in patients with MASH relative to healthy individuals. Taken together, these data suggest that semaglutide may revert the circulating proteome associated with MASH to the proteomic pattern observed in healthy individuals.
- Open Access
- 25 February 2025
- Published by Springer Nature in Nature
- Vol. 639 (8054) , E17
Author Correction: A comprehensive spatio-cellular map of the human hypothalamus
- 25 February 2025
- Published by Springer Nature in Nature
- Vol. 639 (8054) , E17
Open AccessAuthor Correction: A comprehensive spatio-cellular map of the human hypothalamus
- Top Cited PapersOpen Access
- 5 February 2025
- Published by Springer Nature in Nature
- Vol. 639 (8055) , 708-716
A comprehensive spatio-cellular map of the human hypothalamus
The hypothalamus is a brain region that plays a key role in coordinating fundamental biological functions1. However, our understanding of the underlying cellular components and neurocircuitries have, until recently, emerged primarily from rodent studies2,3. Here we combine single-nucleus sequencing of 433,369 human hypothalamic cells with spatial transcriptomics, generating a comprehensive spatio-cellular transcriptional map of the hypothalamus, the ‘HYPOMAP’. Although conservation of neuronal cell types between humans and mice, as based on transcriptomic identity, is generally high, there are notable exceptions. Specifically, there are significant disparities in the identity of pro-opiomelanocortin neurons and in the expression levels of G-protein-coupled receptors between the two species that carry direct implications for currently approved obesity treatments. Out of the 452 hypothalamic cell types, we find that 291 neuronal clusters are significantly enriched for expression of body mass index (BMI) genome-wide association study genes. This enrichment is driven by 426 ‘effector’ genes. Rare deleterious variants in six of these (MC4R, PCSK1, POMC, CALCR, BSN and CORO1A) associate with BMI at population level, and CORO1A has not been linked previously to BMI. Thus, HYPOMAP provides a detailed atlas of the human hypothalamus in a spatial context and serves as an important resource to identify new druggable targets for treating a wide range of conditions, including reproductive, circadian and metabolic disorders.
- 5 February 2025
- Published by Springer Nature in Nature
- Vol. 639 (8055) , 708-716
Top Cited PapersOpen AccessA comprehensive spatio-cellular map of the human hypothalamus
The hypothalamus is a brain region that plays a key role in coordinating fundamental biological functions1. However, our understanding of the underlying cellular components and neurocircuitries have, until recently, emerged primarily from rodent studies2,3. Here we combine single-nucleus sequencing of 433,369 human hypothalamic cells with spatial transcriptomics, generating a comprehensive spatio-cellular transcriptional map of the hypothalamus, the ‘HYPOMAP’. Although conservation of neuronal cell types between humans and mice, as based on transcriptomic identity, is generally high, there are notable exceptions. Specifically, there are significant disparities in the identity of pro-opiomelanocortin neurons and in the expression levels of G-protein-coupled receptors between the two species that carry direct implications for currently approved obesity treatments. Out of the 452 hypothalamic cell types, we find that 291 neuronal clusters are significantly enriched for expression of body mass index (BMI) genome-wide association study genes. This enrichment is driven by 426 ‘effector’ genes. Rare deleterious variants in six of these (MC4R, PCSK1, POMC, CALCR, BSN and CORO1A) associate with BMI at population level, and CORO1A has not been linked previously to BMI. Thus, HYPOMAP provides a detailed atlas of the human hypothalamus in a spatial context and serves as an important resource to identify new druggable targets for treating a wide range of conditions, including reproductive, circadian and metabolic disorders.
- Top Cited PapersOpen Access
- 3 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 267-277
Proteomic changes upon treatment with semaglutide in individuals with obesity
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.
- 3 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 267-277
Top Cited PapersOpen AccessProteomic changes upon treatment with semaglutide in individuals with obesity
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 (n = 1,311) and STEP 2 (n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.
- 4 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (776) , eadk4908
Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist
Glucagon-like peptide-1 (GLP-1) and leptin signal recent feeding and long-term energy stores, respectively, and play complementary roles in the modulation of energy balance. Previous work using single-cell techniques in mice revealed the existence of a population of leptin receptor ( Lepr )–containing dorsomedial hypothalamus (DMH) neurons marked by the expression of GLP-1 receptor ( Glp1r ; LepR Glp1r neurons) that play important roles in the control of feeding and body weight by leptin. Here, we demonstrate the existence of a population of LepR Glp1r neurons in the DMHs of nonhuman primates (NHPs), suggesting the potential translational relevance of these neurons. Consequently, we developed a GLP-1R/LepR dual agonist and demonstrated the physiological activity of both components in vivo using leptin-deficient and Lepr- deficient murine models. We further found roles for LepR Glp1r neurons in mediating the dual agonist’s efficacy on food intake and body weight loss. Ablating Lepr in Glp1r -expressing neurons (Lepr Glp1r KO mice) abrogated the suppression of food intake by the dual agonist. Furthermore, reactivation of Glp1r expression in Lepr neurons on an otherwise Glp1r -null background (Glp1r Lepr Re mice) was sufficient to permit the suppression of food intake and body weight by the dual agonist. Hence, LepR Glp1r neurons represent targets for a GLP-1R/LepR dual agonist that potently reduces food intake and body weight.
- 4 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (776) , eadk4908
Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist
Glucagon-like peptide-1 (GLP-1) and leptin signal recent feeding and long-term energy stores, respectively, and play complementary roles in the modulation of energy balance. Previous work using single-cell techniques in mice revealed the existence of a population of leptin receptor ( Lepr )–containing dorsomedial hypothalamus (DMH) neurons marked by the expression of GLP-1 receptor ( Glp1r ; LepR Glp1r neurons) that play important roles in the control of feeding and body weight by leptin. Here, we demonstrate the existence of a population of LepR Glp1r neurons in the DMHs of nonhuman primates (NHPs), suggesting the potential translational relevance of these neurons. Consequently, we developed a GLP-1R/LepR dual agonist and demonstrated the physiological activity of both components in vivo using leptin-deficient and Lepr- deficient murine models. We further found roles for LepR Glp1r neurons in mediating the dual agonist’s efficacy on food intake and body weight loss. Ablating Lepr in Glp1r -expressing neurons (Lepr Glp1r KO mice) abrogated the suppression of food intake by the dual agonist. Furthermore, reactivation of Glp1r expression in Lepr neurons on an otherwise Glp1r -null background (Glp1r Lepr Re mice) was sufficient to permit the suppression of food intake and body weight by the dual agonist. Hence, LepR Glp1r neurons represent targets for a GLP-1R/LepR dual agonist that potently reduces food intake and body weight.
- Open Access
- 26 November 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (20) , 1697-1698
GLP-1 for Treating Obesity—Origin, History, and Evolution
In this Viewpoint, 2024 Lasker-DeBakey Clinical Medical Research Award winner Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the treatment of patients with obesity.
- 26 November 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (20) , 1697-1698
Open AccessGLP-1 for Treating Obesity—Origin, History, and Evolution
In this Viewpoint, 2024 Lasker-DeBakey Clinical Medical Research Award winner Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the treatment of patients with obesity.
- Open Access
- 20 February 2024
- Published by Wiley in Genetic Epidemiology
- Vol. 48 (4) , 151-163
Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis‐multivariable Mendelian randomization to GLP1R gene region
Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight into the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F statistics for dimension‐reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two‐sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension‐reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes (T2D). Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than T2D liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue‐specific analyses prioritized brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.
- 20 February 2024
- Published by Wiley in Genetic Epidemiology
- Vol. 48 (4) , 151-163
Open AccessRobust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis‐multivariable Mendelian randomization to GLP1R gene region
Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight into the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F statistics for dimension‐reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two‐sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension‐reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes (T2D). Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than T2D liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue‐specific analyses prioritized brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.